Ameriprise’s Aimmune Therapeutics AIMT Stock Holding History

Ameriprise’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-60,497	Closed	-$2.08M	–	3896
2020 Q3	$2.08M	Buy	+60,497	New	+$1.29M	﹤0.01%	2641
2017 Q1	–	Sell	-55,773	Closed	-$1.14M	–	3718
2016 Q4	$1.14M	Buy	+55,773	New	+$1.14M	﹤0.01%	2905

Ameriprise's AIMT Position: Q4 2020 in Review

Ameriprise sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 60,497 shares — an estimated $2.08M sold.

Ameriprise first reported a position in AIMT in Q4 2016 and held it in 2 quarters. The position peaked at $2.08M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Ameriprise reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Ameriprise sold 60,497 Aimmune Therapeutics shares in Q4 2020, an estimated $2.08M.
Ameriprise first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 2 quarters.
Ameriprise's Aimmune Therapeutics position peaked at $2.08M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Ameriprise's 13F filing for Q4 2020, filed 12 Feb 2021.